Stephen A. Harrison
725 works · 72,342 citations · h-index 121
Top works
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study
- A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United States
- Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- The natural history of nonalcoholic fatty liver disease: a clinical histopathological study
- A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
- Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease
- Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- Diagnosis and Therapy of Nonalcoholic Steatohepatitis
- From NAFLD to MAFLD: Implications of a Premature Change in Terminology
- FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
- A multisociety Delphi consensus statement on new fatty liver disease nomenclature
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial